Colistin and Polymyxin B

Colistin and Polymyxin B is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

  • Colistimethate sodium (colistin; 2.5–5 mg/kg/d IV divided q12h) and polymyxin B (15,000–25,000 units/kg/d IV divided q12h) are bactericidal polypeptide antibiotics that kill gram-negative bacteria by disrupting the cell membrane. These drugs have reemerged in the treatment of multidrug-resistant gram-negative bacilli but are inactive against Proteus, Providencia, and Serratia.
  • These medications should only be given under the guidance of an experienced clinician because parenteral therapy has significant CNS and nephrotoxicity. Inhaled colistin (75–150 mg q12h given by nebulizer) is better tolerated than the IV formulation, generally causing only mild upper airway irritation, and has some effectiveness as adjunctive therapy for multidrug-resistant P. aeruginosa or Acinetobacter pulmonary infections.

-- To view the remaining sections of this topic, please or --

General Principles

  • Colistimethate sodium (colistin; 2.5–5 mg/kg/d IV divided q12h) and polymyxin B (15,000–25,000 units/kg/d IV divided q12h) are bactericidal polypeptide antibiotics that kill gram-negative bacteria by disrupting the cell membrane. These drugs have reemerged in the treatment of multidrug-resistant gram-negative bacilli but are inactive against Proteus, Providencia, and Serratia.
  • These medications should only be given under the guidance of an experienced clinician because parenteral therapy has significant CNS and nephrotoxicity. Inhaled colistin (75–150 mg q12h given by nebulizer) is better tolerated than the IV formulation, generally causing only mild upper airway irritation, and has some effectiveness as adjunctive therapy for multidrug-resistant P. aeruginosa or Acinetobacter pulmonary infections.

There's more to see -- the rest of this entry is available only to subscribers.